We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

4 hedge funds and large institutions have $3.29K invested in Statera Biopharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% less funds holding

Funds holding: 29 → 4 (-25)

98% less capital invested

Capital invested by funds: $200K → $3.29K (-$197K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 25

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-25
Holders Change %
-86.21%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$59K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$30.7K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$20.6K
4
Northern Trust
Northern Trust
Illinois
-$13.9K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
– -$5 -60 Closed
1
2

STAB Hedge Fund Activity: Q1 2023 in Review

4 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2023, worth a combined $3.29K — down 98% from $200K a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of STAB and 0 opened new positions — a net loss of 25 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $59K sold.

  • 4 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2023, down from 29 in Q4 2022.
  • Funds reported $3.29K of Statera Biopharma, Inc. Common Stock stock for Q1 2023, down 98% quarter-over-quarter.
  • 0 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2023 and 25 closed out, a net change of -25 holders.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q1 2023 was Renaissance Technologies, an estimated $59K sold.

Based on aggregated 13F filings for Q1 2023.